文献速递肿瘤 PET/CT骨显像与常规 SPECT

纳武利尤单抗治疗患者的免疫相关关节炎FDG PET/CT表现

FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab.
PubMed 文献 · Clin Nucl Med · 2022-10-15

本文报告一例56岁原发性恶性黑色素瘤女性患者,接受纳武利尤单抗治疗5个月后行全身FDG PET/CT评估疗效,发现四肢主要关节代谢活性增高,与既往PET/CT相比为新发表现,判读为免疫相关关节炎并发症。

要点

  • 免疫检查点抑制剂治疗中可出现免疫相关关节炎。
  • 纳武利尤单抗治疗后FDG PET/CT示四肢主要关节代谢增高。
  • 该表现与既往PET/CT相比为新发,判读为免疫相关关节炎并发症。

核心结论

  • 纳武利尤单抗治疗5个月后全身FDG PET/CT示四肢主要关节代谢活性增高,与既往FDG PET/CT相比为新发表现,判读为免疫相关关节炎并发症。

研究设计与样本

  • 本文为影像病例报告,对象为1例56岁原发性恶性黑色素瘤女性患者。

主要发现

  • 该患者接受纳武利尤单抗治疗5个月,治疗后行全身FDG PET/CT评估疗效。
  • FDG PET/CT示四肢主要关节代谢活性增高,与既往FDG PET/CT相比为新发表现。
  • 该表现判读为免疫相关关节炎并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors are a new and different treatment option in many of solid tumors, but with many recognized immune-related adverse side effects. In this interesting image, we are presenting a 56-year-old woman with primary malignant melanoma who underwent nivolumab therapy for 5 months, and a posttreatment whole-body FDG PET/CT scan for treatment response evaluation demonstrated increased metabolic activity in the entire major joints of the upper and lower extremities. This was a new finding compared with previous FDG PET/CT scan and was interpreted as an immune-related arthritis complication.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bayat M, Doroudinia A, Karam MB, et al. FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab. Clin Nucl Med. 2022. PMID: 36252811. doi:10.1097/RLU.0000000000004429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。